Frazier Lifesciences Acquisition Corp

admitted from the HISTORICAL census (EDGAR's SIC 6770 registrant list, walked in full: 3,325 registrants, 1,167 of which ever priced an IPO). The live discovery job cannot reach this registrant — it reads the filing tape, and this one stopped filing. Admission rule: src/lib/universe-admit.ts. SIC 6770 (Blank Checks); 424B 0001104659-20-134286 priced 2020-12-10; common ticker FLAC off 8-K 0001193125-22-285506 (2022-11-15); lifecycle EXITED. Ending PROVEN, not inferred: CLOSED per Form 25 0001354457-22-000662 (2022-11-22) — Form 25 filed under 17 CFR 240.12d2-2(a)(3) — the rule for securities that "have come to evidence other securities in substitution therefor", i.e. the shares became the successor's (class: Warant). ipoSizeM and deadline left NULL: gross-proceeds prose conflates the over-allotment with the offering, and a charter deadline belonging to a vehicle that has ended is a date nobody can act on. ipoDate is the 424B pricing date.

warrantStrike=11.5, unitSeparationDays=52 from the definitive prospectus (0001104659-20-134286). NOT FILLED: warrantCallPrice — no stated candidate; rightShareRatio — no stated candidate

sponsor "Approximate Percentage of Voting Control Frazier Lifesciences Sponsor LLC" sourced from prospectus definition (10-K/A) acc 0001193125-21-170830.

[CLOSED-2.01] SEC accession 0001193125-22-292061 (Form 8-K, item 2.01 Completion of Acquisition or Disposition of Assets); the cover's date of earliest event reported is 2022-11-22. That is the SEC's own date for this report and NOT necessarily the closing day — an 8-K may cover several events, and where the two differ the closing date is in the quoted sentence below. Target read STRUCTURALLY from the merger agreement's party list — the party that is neither the registrant (identified by the filing's own cover page) nor a merger sub (identified by the clause making it a subsidiary of another party) nor an accommodation party (identified by a "solely for purposes of" joinder), and it was the only one left. The same party list also names "NewAmsterdam Pharma Holding B.V.", which differ from the recorded target only in legal form and are treated as the same identity; the first-named spelling is the one recorded. The sentence it was read from: "☐ INTRODUCTORY NOTE On November 22, 2022 (the "Closing Date"), Frazier Lifesciences Acquisition Corporation, a Cayman Islands exempted company ("FLAC"), consummated the previously announced business combination (the "Business Combination") pursuant to the terms of the Business Combination Agreement (the "Business Combination Agreement"), dated July 25, 2022, by and among FLAC, NewAmsterdam Pharma Company B.V., a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ) incorporated under the laws of the Netherlands ("Holdco"), NewAmsterdam Pharma Holding B.V., a private company with limited liability ( besloten vennootschap met beperkte aansprakelijkheid ) incorporated under the laws of the Netherlands ("NewAmsterdam Pharma") and NewAmsterdam Pharma Investment Corporation, a Cayman Islands exempted company ("Merger Sub")." No deal value is set — an item-2.01 heading is not a figure. No date column is set: Deal has announcedAt, voteDate and expectedCloseAt and nowhere to record an actual close, so the SEC's date is kept here until that column exists. [DEAL-STRUCTURE-MINED] minCashM=250, terminationFeeM=1 from primary filings (0001193125-22-264485).

entity created from the filed target name; no About paragraph on file, so every other field awaits a sourced read

OTHER -> BIOTECH, on 425 0001193125-22-286672: "NewAmsterdam is a private clinical-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where traditi"